v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows from operating activities:    
Net income (loss) $ (2,798,489) $ (4,353,023)
(Income) loss from discontinued operation, net of tax provision (654,388) 2,823,421
Net loss from continuing operations (3,452,877) (1,529,602)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation 37,919 5,152
Amortization of intangible asset 64,112 32,056
Lease expense of operating lease assets 87,881 51,805
Provision of allowance for expected credit loss on accounts receivable 133,772
Provision of allowance for expected credit loss on loan receivable 350,000
Amortization of discount and bond issuance cost 109,753
Accrued interest expense of convertible debt 10,338 40,541
Deferred tax expense (78,855) (8,014)
Interest income (177,765) (11,645)
Stock-based compensation expense for consulting services 2,089,460
Changes in operating assets and liabilities:    
Accounts receivable (517,421) (337,288)
Note receivables 65,152
Inventories 74,510 (216,538)
Right of return asset 15,415
Prepayment, deposit and other receivable (2,926,217) (100,923)
Accounts payables (38,079) 299,114
Contract liabilities (11,508) 42,168
Accrued expense and other payables 846,065 807,540
Refund liabilities 162,204
Tax payable 185,250 26,608
Operating lease liabilities (70,171) (80,709)
Net cash used in operating activities from continuing operations (3,041,062) (979,735)
Cash flows from investing activities:    
Purchase of furniture and equipment (10,898)
Payment for leasehold improvement (21,902)
Net cash payment for asset acquisition (552,721)
Loan to a third party (8,497,511) (561,901)
Net cash used in investing activities from continuing operations (8,497,511) (1,147,422)
Cash flows from financing activities:    
Repayment of loans (25,411)
Net proceeds from issuance of convertible notes 755,512
Repayment of principal of convertible debt (432,948)
Repayment of equipment and vehicle loans (7,827)
Advances from Hupan Pharmaceutical prior to acquisition 276,365
Proceeds from initial public offering, net of share issuance costs 5,351,281
Proceeds from a private placement 8,236,231
Repayment to shareholders (592,159)
Net cash provided by financing activities from continuing operations 7,770,045 5,790,999
CASH FLOWS FROM DISCONTINUED OPERATION    
Operating activities (1,383,504) (1,191,569)
Investing activities (79,728)
Financing activities 1,337,183 (1,008,452)
Cash sold in connection with sales of ABL Chicago (167,536)
Net cash used in discontinued operation (213,857) (2,279,749)
Effect of exchange rate changes on cash 326,631 (8,386)
Net (decrease) increase in cash (3,655,754) 1,375,707
Cash, beginning of the period 4,956,060 123,550
Cash, end of the period 1,300,306 1,499,257
Less: cash and cash equivalents of discontinued operations 241,867
Cash, end of the period for continuing operations 1,300,306 1,257,390
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:    
Cash paid for income tax 17,043
Cash paid for interest 454,850 67,704
NON-CASH ACTIVITIES    
Right of use assets obtained in exchange for operating lease obligations 1,447,494
Right of use assets obtained in exchange for finance lease obligation 89,003
SUPPLEMENTAL SCHEDULE OF NON-CASH IN INVESTING AND FINANCING ACTIVITIES    
Property additions included in loan payable 69,219 102,235
Additions to leasehold improvement through accounts payable and other payable 123,176
Due to shareholder offset against due from related parties 311,185
Convertible notes converted to common shares 512,733
Issuance of common shares in exchange for consulting service $ 4,422,700